Natick, MA, February 6, 2024 – Cytodigm, a biopharmaceutical company developing innovative delivery systems for nucleic acid therapeutics, announced its license agreement with Cour Pharmaceuticals Development Corp. (“Cour”). Under the agreement, in return for undisclosed financial terms, Cytodigm granted Cour and its sublicensees Takeda and Ironwood an exclusive license to its Zetafinity® Technology Patents in fields outside oncology.
“Zetafinity® exemplifies the groundbreaking capabilities of each of Cytodigm’s drug delivery platforms, and we are very pleased to enable Cour and its global pharmaceutical partners to develop important new medicines with this valuable intellectual property.,” said Dr. Bin Wu, Cytodigm’s Founder and CEO, “We look forward to seeing Cour’s progress on its clinical partnerships with Takeda and Ironwood, and the success in its own clinical and pre-clinical programs.”
About Cytodigm
Cytodigm is a preclinical-stage biopharmaceutical company developing next-generation therapeutics by leveraging its proprietary technologies to increase targetability and delivery efficiency while reducing immunogenicity and toxicity. Cytodigm is advancing CytofinityTM and SigfinityTM, its lipid-based nanoparticle platforms, to deliver nucleic acid therapeutics for in vivo cell, gene, and immune therapy to various organs and cells. In the meantime, Cytodigm is applying its Zetafinity® polymer nanoparticles, a clinically proven delivery system, to enable the treatment of solid tumors.
Cytodigm’s business model is to develop therapeutics to clinical proof of concept for its technology platforms, leverage platform value through collaborations with other biopharmaceutical companies, and out-license the technology for different indications.
Contact
Bin Wu, Ph.D.
Founder & CEO
bwu@cytodigm.com
